



Panion's dog safety study experience a slight delay

Panion Animal Health AB develops a unique gene therapy treatment for dogs with idiopathic epilepsy. A safety study in dogs is currently running at the University of Copenhagen under the lead of Associate Professor David Woldbye, Department of Neuroscience, KU. Preliminary results from the study were expected in Q2, but due to circumstances outside Panion's influence, Panion has just been informed that this timing has been slightly delayed into Q3.

"The access to gene therapy facilities at Copenhagen University is limited and the study was confronted with overbooking and issues with availability of staff and equipment. We wish to inform the market about this slight delay to maintain the trust in our information flow and to avoid speculations. It is important to note that nothing negative has been seen in the study so far, and that we are fully confident with the study conduct" says CEO in Panion, Anja Holm.

This press release contains information which Panion Animal Health AB is obliged to publish according to the EU market abuse regulation (MAR). This information was submitted by Panion's CEO, Anja E. H. Holm, for publication on June 28 2018.

For further information, please contact:

Ánja E. H. Holm, CEO | +45-22 94 66 00 anja.holm@panion-animalhealth.com

Developing animal health – In Panion, we want to improve the quality of life for animals suffering from chronic diseases. We are convinced that gene therapy has promising prospects. Our aim is to develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, based on CombiGene AB's technology and platform. Panion Animal Health AB is listed at Spotlight Stock Market.

Panion Animal Health AB

Frykholmsgatan 11, 281 31 Hässleholm, Sweden info@panion-animalhealth.com

linkedin.com/company/panion-animalhealth



twitter.com/panionanihealth panion-animalhealth.com/newsletter



panion-animalhealth.com

